Back

Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75

Ishimaru, H.; Nishimura, M.; Tjan, L. H.; Sutandhio, S.; Marini, M. I.; Effendi, G. B.; Shigematsu, H.; Kato, K.; Hasegawa, N.; Aoki, K.; Kurahashi, Y.; Furukawa, K.; Shinohara, M.; Nakamura, T.; Arii, J.; Nagno, T.; Nakamura, S.; Sano, S.; Iwata, S.; Mori, Y.

2022-09-02 microbiology
10.1101/2022.09.02.506305 bioRxiv
Show abstract

We identified novel neutralizing monoclonal antibodies against SARS-CoV-2 variants (including Omicron) from individuals received two doses of mRNA vaccination after they had been infected with wildtype. We named them MO1, MO2 and MO3. MO1 shows high neutralizing activity against authentic variants: D614G, Delta, BA.1, BA.1.1, BA.2, and BA.2.75 and BA.5. Our findings confirm that the wildtype-derived vaccination can induce neutralizing antibodies that recognize the epitopes conserved among the SARS-CoV-2 variants (including BA.5 and BA.2.75). The monoclonal antibodies obtained herein could serve as novel prophylaxis and therapeutics against not only current SARS-CoV-2 viruses but also future variants that may arise.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
iScience
○ 1154 papers in training set
Top 0.2%
11.9%
Similar papers in this journal
2
Journal of Virology
● 499 papers in training set
Top 1%
6.7%
Similar papers in this journal
3
eLife
● 5828 papers in training set
Top 17%
6.7%
Similar papers in this journal
4
Scientific Reports
○ 3612 papers in training set
Top 16%
5.5%
Similar papers in this journal
5
Antiviral Research
○ 50 papers in training set
Top 0.2%
4.8%
Similar papers in this journal
6
Cell Reports
○ 1498 papers in training set
Top 8%
4.8%
7
mBio
● 833 papers in training set
Top 4%
4.4%
8
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.1%
3.5%
9
PLOS Pathogens
● 820 papers in training set
Top 4%
3.4%
50% of probability mass above
10
Cell Reports Medicine
○ 153 papers in training set
Top 0.9%
3.2%
11
Frontiers in Immunology
○ 638 papers in training set
Top 4%
2.4%
12
Vaccine
○ 203 papers in training set
Top 1.0%
2.4%
13
Cell Discovery
○ 57 papers in training set
Top 0.3%
2.4%
14
Microbiology Spectrum
● 469 papers in training set
Top 6%
2.1%
15
Glycobiology
◐ 35 papers in training set
Top 0.1%
2.1%
16
Frontiers in Cellular and Infection Microbiology
○ 109 papers in training set
Top 2%
1.7%
17
International Journal of Infectious Diseases
○ 129 papers in training set
Top 1%
1.7%
18
Heliyon
○ 152 papers in training set
Top 4%
1.7%
19
Emerging Microbes & Infections
○ 74 papers in training set
Top 0.7%
1.5%
20
Viruses
○ 332 papers in training set
Top 3%
1.5%
21
PLOS ONE
● 5266 papers in training set
Top 53%
1.1%
22
Cellular & Molecular Immunology
○ 14 papers in training set
Top 0.1%
1.0%
23
Communications Biology
○ 993 papers in training set
Top 26%
1.0%
24
Nature Communications
○ 5641 papers in training set
Top 54%
1.0%
25
Virologica Sinica
○ 11 papers in training set
Top 0.2%
1.0%
26
Applied Microbiology and Biotechnology
○ 32 papers in training set
Top 0.7%
0.9%
27
Journal of Molecular Cell Biology
◐ 22 papers in training set
Top 0.3%
0.8%
28
Science China Life Sciences
○ 29 papers in training set
Top 0.6%
0.8%
29
Human Vaccines & Immunotherapeutics
○ 25 papers in training set
Top 0.5%
0.8%
30
Cell
○ 431 papers in training set
Top 10%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.